Johnson & Johnson

Johnson & Johnson Highlights Promising Data on Investigational Autoantibody Drug Nipocalimab

SPRING HOUSE, PA — Johnson & Johnson has unveiled groundbreaking findings on nipocalimab, an investigational FcRn blocker, in a recent publication in mAbs. The study showcases the drug’s high-affinity binding capabilities …

Johnson & Johnson Highlights Promising Data on Investigational Autoantibody Drug Nipocalimab Read More

Office Practicum

Office Practicum Launches SocialSavvy to Revolutionize Pediatric Practices’ Social Media Presence

FORT WASHINGTON, PA — Office Practicum has announced the rollout of SocialSavvy, an innovative social media management tool designed specifically for pediatric practices. The platform aims to streamline the delivery of …

Office Practicum Launches SocialSavvy to Revolutionize Pediatric Practices’ Social Media Presence Read More

INOVIO Pharmaceuticals

INOVIO’s INO-3107 Shows Powerful Potential for Treating Recurrent Respiratory Papillomatosis

PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) has unveiled promising peer-reviewed results from its Phase 1/2 clinical trial for INO-3107, a cutting-edge DNA medicine designed to treat recurrent respiratory papillomatosis (RRP). …

INOVIO’s INO-3107 Shows Powerful Potential for Treating Recurrent Respiratory Papillomatosis Read More